OraSure Insider Buys Signal Confidence Ahead of 2026 FDA Milestones
Executive buys reveal OraSure’s confidence: insider purchases, a share‑repurchase program, and upcoming FDA approvals could lift the $206 M stock, offering investors a hopeful outlook.
4 minutes to read
